Adrenergic dysfunction in patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: A systematic review and meta-analysis.
adrenergic function
adrenergic receptors
catecholamines
fibromyalgia
myalgic encephalomyelitis/chronic fatigue syndrome
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
24
06
2024
accepted:
08
09
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) are comorbid disorders with overlapping symptoms. Research highlights autonomic dysfunction compared to healthy individuals, particularly involving the sympathetic branch. While past reviews focused on neurophysiological assessments, this systematic review summarises biological adrenergic markers, offering deeper insights into the observed sympathetic dysfunction in ME/CFS and FM aiming to identify targetable pathophysiological mechanisms. A systematic search was performed on PubMed, Web of Science, Embase and Scopus. Studies investigating peripheral biological markers of adrenergic function in patients with ME/CFS or FM compared to healthy controls at baseline were included. Meta-analyses were performed using R statistical software. This meta-analysis of 37 studies, encompassing 543 ME/CFS patients and 651 FM patients, compared with 747 and 447 healthy controls, respectively, revealed elevated adrenaline (SMD = .49 [.31-.67]; Z = 5.29, p < .01) and β1 adrenergic receptor expression (SMD = .79 [.06-1.52]; Z = 2.13; p = .03) in blood of ME/CFS patients at rest. Additionally, patients with ME/CFS had a greater increase in the expression of α2A adrenergic receptor (AR, SMD = .57 [.18-.97]; Z = 2.85, p < .01), β2 AR (SMD = .41 [.02-.81]; Z = 2.04; p = .04) and COMT (SMD = .42 [.03-.81]; Z = 2.11; p = .03) after exercise and an increased response of noradrenaline to an orthostatic test (SMD = .11 [-.47 to -.70]; Z = 2.10; p = .04), both found in blood. FM patients showed no significant differences at baseline but exhibited a diminished adrenaline response to exercise (SMD = -.79 [-1.27 to -.30]; Z = -3.14; p < .01). This systematic review and meta-analysis revealed adrenergic dysfunction mainly in patients with ME/CFS. Higher baseline adrenaline levels and atypical responses to exercise in ME/CFS indicate that sympathetic dysfunction, underscored by adrenergic abnormalities, is more involved in the pathophysiology of ME/CFS rather than FM.
Sections du résumé
BACKGROUND
BACKGROUND
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) are comorbid disorders with overlapping symptoms. Research highlights autonomic dysfunction compared to healthy individuals, particularly involving the sympathetic branch. While past reviews focused on neurophysiological assessments, this systematic review summarises biological adrenergic markers, offering deeper insights into the observed sympathetic dysfunction in ME/CFS and FM aiming to identify targetable pathophysiological mechanisms.
METHODS
METHODS
A systematic search was performed on PubMed, Web of Science, Embase and Scopus. Studies investigating peripheral biological markers of adrenergic function in patients with ME/CFS or FM compared to healthy controls at baseline were included. Meta-analyses were performed using R statistical software.
RESULTS
RESULTS
This meta-analysis of 37 studies, encompassing 543 ME/CFS patients and 651 FM patients, compared with 747 and 447 healthy controls, respectively, revealed elevated adrenaline (SMD = .49 [.31-.67]; Z = 5.29, p < .01) and β1 adrenergic receptor expression (SMD = .79 [.06-1.52]; Z = 2.13; p = .03) in blood of ME/CFS patients at rest. Additionally, patients with ME/CFS had a greater increase in the expression of α2A adrenergic receptor (AR, SMD = .57 [.18-.97]; Z = 2.85, p < .01), β2 AR (SMD = .41 [.02-.81]; Z = 2.04; p = .04) and COMT (SMD = .42 [.03-.81]; Z = 2.11; p = .03) after exercise and an increased response of noradrenaline to an orthostatic test (SMD = .11 [-.47 to -.70]; Z = 2.10; p = .04), both found in blood. FM patients showed no significant differences at baseline but exhibited a diminished adrenaline response to exercise (SMD = -.79 [-1.27 to -.30]; Z = -3.14; p < .01).
CONCLUSION
CONCLUSIONS
This systematic review and meta-analysis revealed adrenergic dysfunction mainly in patients with ME/CFS. Higher baseline adrenaline levels and atypical responses to exercise in ME/CFS indicate that sympathetic dysfunction, underscored by adrenergic abnormalities, is more involved in the pathophysiology of ME/CFS rather than FM.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14318Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Natelson BH. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: definitions, similarities, and differences. Clin Ther. 2019;41(4):612‐618.
Ramírez‐Morales R, Bermúdez‐Benítez E, Martínez‐Martínez LA, Martínez‐Lavín M. Clinical overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta‐analysis. Autoimmun Rev. 2022;21(8):103129.
Brenna E, Gitto L. The economic burden of chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME): an initial summary of the existing evidence and recommendations for further research. Eur J Pers Cent Healthc. 2017;5(3):413‐420.
Meeus M, Goubert D, De Backer F, et al. Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systematic review. Semin Arthritis Rheum. 2013;43(2):279‐287.
Martínez‐Martínez LA, Mora T, Vargas A, Fuentes‐Iniestra M, Martínez‐Lavín M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case‐control studies. J Clin Rheumatol. 2014;20(3):146‐150.
Van Cauwenbergh D, Nijs J, Kos D, Van Weijnen L, Struyf F, Meeus M. Malfunctioning of the autonomic nervous system in patients with chronic fatigue syndrome: a systematic literature review. Eur J Clin Investig. 2014;44(5):516‐526.
Nelson MJ, Bahl JS, Buckley JD, Thomson RL, Davison K. Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review and meta‐analysis. Medicine (Baltimore). 2019;98(43):e17600.
Pereira VH, Campos I, Sousa N. The role of autonomic nervous system in susceptibility and resilience to stress. Curr Opin Behav Sci. 2017;14:102‐107.
Pongratz G, Straub RH. Chronic effects of the sympathetic nervous system in inflammatory models. Neuroimmunomodulation. 2023;30(1):113‐134.
Harris KF, Matthews KA. Interactions between autonomic nervous system activity and endothelial function: a model for the development of cardiovascular disease. Psychosom Med. 2004;66(2):153‐164.
Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation. 2012;19(6):343‐351.
Giske L, Vøllestad NK, Mengshoel AM, Jensen J, Knardahl S, Røe C. Attenuated adrenergic responses to exercise in women with fibromyalgia—a controlled study. Eur J Pain. 2008;12(3):351‐360.
Light KC, Agarwal N, Iacob E, et al. Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology. 2013;38(12):2983‐2995.
Maekawa K, Twe C, Lotaif A, Chiappelli F, Clark GT. Function of beta‐adrenergic receptors on mononuclear cells in female patients with fibromyalgia. J Rheumatol. 2003;30(2):364‐368.
Maes M, Libbrecht I, Delmeire L, et al. Changes in platelet alpha‐2‐adrenoceptors in fibromyalgia: effects of treatment with antidepressants. Neuropsychobiology. 1999;40(3):129‐133.
Rus A, Molina F, Del Moral ML, Ramírez‐Expósito MJ, Martínez‐Martos JM. Catecholamine and indolamine pathway: a case‐control study in fibromyalgia. Biol Res Nurs. 2018;20(5):577‐586.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Ahmed I. MetaChange: A Shiny App for Calculating Mean and Standard Deviation Changes in Meta‐Analysis. 2023 https://ixhtiaq.shinyapps.io/Mean_SD_Change_Calculator/2023
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta‐analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153‐160.
Ahmed I, Mustafaoglu R, Benkhalifa N, Yakhoub YH. Does noninvasive brain stimulation combined with other therapies improve upper extremity motor impairment, functional performance, and participation in activities of daily living after stroke? A systematic review and meta‐analysis of randomized controlled trial. Top Stroke Rehabil. 2023;30(3):213‐234.
Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosci. 2003;113(5):683‐701.
Boneva RS, Decker MJ, Maloney EM, et al. Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population‐based study. Auton Neurosci. 2007;137(1–2):94‐101.
Wyller VB, Vitelli V, Sulheim D, et al. Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross‐sectional study. J Transl Med. 2016;14(1):121.
Kristiansen MS, Stabursvik J, O'Leary EC, et al. Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein‐Barr virus infection: an exploratory cross‐sectional study. Brain Behav Immun. 2019;80:551‐563.
Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo‐controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med. 1998;158(8):908‐914.
Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci. 2000;320(1):1‐8.
Streeten DH. Role of impaired lower‐limb venous innervation in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci. 2001;321(3):163‐167.
Timmers HJ, Wieling W, Soetekouw PM, Bleijenberg G, Van Der Meer JW, Lenders JW. Hemodynamic and neurohumoral responses to head‐up tilt in patients with chronic fatigue syndrome. Clin Auton Res. 2002;12(4):273‐280.
Ottenweller JE, Sisto SA, McCarty RC, Natelson BH. Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology. 2001;43(1):34‐41.
Wyller VB, Godang K, Mørkrid L, Saul JP, Thaulow E, Walløe L. Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics. 2007;120(1):e129‐e137.
Strahler J, Fischer S, Nater UM, Ehlert U, Gaab J. Norepinephrine and epinephrine responses to physiological and pharmacological stimulation in chronic fatigue syndrome. Biol Psychol. 2013;94(1):160‐166.
Keech A, Vollmer‐Conna U, Barry BK, Lloyd AR. Gene expression in response to exercise in patients with chronic fatigue syndrome: a pilot study. Front Physiol. 2016;7:421.
Loevinger BL, Muller D, Alonso C, Coe CL. Metabolic syndrome in women with chronic pain. Metabolism. 2007;56(1):87‐93.
Kaufmann I, Schelling G, Eisner C, et al. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology. 2008;33(5):676‐685.
Katar M, Deveci H, Deveci K. Evaluation of clinical relationship of serum niacin and dopamine levels in patients with fibromyalgia syndrome. Turk J Phys Med Rehabil. 2022;68(1):84‐90.
van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol. 1992;21(1):35‐37.
Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic‐pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med. 1999;106(5):534‐543.
Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic‐pituitary‐adrenal axis to interleukin‐6: a pilot study in fibromyalgia. Arthritis Rheum. 2000;43(4):872‐880.
Furlan R, Colombo S, Perego F, et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol. 2005;32(9):1787‐1793.
Giske L, Røe C, Knardahl S, Vøllestad NK. Pain and sympathoadrenal responses to dynamic exercise in women with the fibromyalgia syndrome. J Musculoskelet Pain. 2007;15(4):25‐38.
Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, Maixner W. Adrenergic dysregulation and pain with and without acute beta‐blockade in women with fibromyalgia and temporomandibular disorder. J Pain. 2009;10(5):542‐552.
Kadetoff D, Kosek E. Evidence of reduced sympatho‐adrenal and hypothalamic‐pituitary activity during static muscular work in patients with fibromyalgia. J Rehabil Med. 2010;42(8):765‐772.
Xiao Y, He W, Russell IJ. Genetic polymorphisms of the beta2‐adrenergic receptor relate to guanosine protein‐coupled stimulator receptor dysfunction in fibromyalgia syndrome. J Rheumatol. 2011;38(6):1095‐1103.
Riva R, Mork PJ, Westgaard RH, Okkenhaug Johansen T, Lundberg U. Catecholamines and heart rate in female fibromyalgia patients. J Psychosom Res. 2012;72(1):51‐57.
Bote ME, Garcia JJ, Hinchado MD, Ortega E. Fibromyalgia: anti‐inflammatory and stress responses after acute moderate exercise. PLoS One. 2013;8(9):e74524.
Rizzi M, Radovanovic D, Santus P, et al. Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients. Clin Exp Rheumatol. 2017;35 Suppl 105(3):74‐80.
Salgado ASI, Takemoto MH, de Souza C, et al. Gentle touch therapy, pain relief and neuroplasticity at baseline in fibromyalgia syndrome: a randomized, multicenter trial with six‐month follow‐up. J Clin Med. 2022;11(16):4898.
Meyer JD, Light AR, Shukla SK, et al. Post‐exertion malaise in chronic fatigue syndrome: symptoms and gene expression. Fatigue: Biomed, Health Behav. 2013;1(4):190‐209.
White AT, Light AR, Hughen RW, Vanhaitsma TA, Light KC. Differences in metabolite‐detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom Med. 2012;74(1):46‐54.
Light AR, Bateman L, Jo D, et al. Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome and fibromyalgia syndrome. J Intern Med. 2012;271(1):64‐81.
Light AR, White AT, Hughen RW, Light KC. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J Pain. 2009;10(10):1099‐1112.
Motiejunaite J, Amar L, Vidal‐Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines. Ann Endocrinol. 2021;82(3):193‐197.
Zouhal H, Jacob C, Delamarche P, Gratas‐Delamarche A. Catecholamines and the effects of exercise training and gender. Sports Med. 2008;38(5):401‐423.
Laustiola K, Uusitalo A, Koivula T, et al. Divergent effects of atenolol, practolol and propranolol on the peripheral metabolic changes induced by dynamic exercise in healthy men. Eur J Clin Pharmacol. 1983;25(3):293‐297.
Kocyigit BF, Akyol A. Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases, and autonomic cardiovascular system involvement in fibromyalgia syndrome. Clin Rheumatol. 2023;42(3):645‐652.
Schutzer SE, Liu T, Tsai CF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia are indistinguishable by their cerebrospinal fluid proteomes. Ann Med. 2023;55(1):2208372.
Abbi B, Natelson BH. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the ‘single syndrome’ hypothesis. QJM. 2013;106(1):3‐9.
Słomko J, Estévez‐López F, Kujawski S, et al. Autonomic phenotypes in chronic fatigue syndrome (CFS) are associated with illness severity: a cluster analysis. J Clin Med. 2020;9(8):2531.
Bynke A, Julin P, Gottfries CG, Heidecke H, Scheibenbogen C, Bergquist J. Autoantibodies to beta‐adrenergic and muscarinic cholinergic receptors in Myalgic encephalomyelitis (ME) patients—a validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health. 2020;7:100107.
Danilenko OV, Gavrilova NY, Churilov LP. Chronic fatigue exhibits heterogeneous autoimmunity characteristics which reflect etiology. Pathophysiology. 2022;29(2):187‐199.
Freitag H, Szklarski M, Lorenz S, et al. Autoantibodies to Vasoregulative G‐protein‐coupled receptors correlate with symptom severity, autonomic dysfunction and disability in Myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Med. 2021;10(16):3675.
Hartwig J, Sotzny F, Bauer S, et al. IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain Behav Immun Health. 2020;3:100047.
Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32‐39.
Scherbakov N, Szklarski M, Hartwig J, et al. Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail. 2020;7(3):1064‐1071.
Szklarski M, Freitag H, Lorenz S, et al. Delineating the association between soluble CD26 and autoantibodies against G‐protein coupled receptors, immunological and cardiovascular parameters identifies distinct patterns in post‐infectious vs non‐infection‐triggered myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2021;12:644548.
Tanaka S, Kuratsune H, Hidaka Y, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003;12(2):225‐230.